Clinical trials
Terminated Immunologic Deficiency Syndromes trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
19 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2009 | 4 |
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2019 | 1 |
| 2022 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 19 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 3 |
| Columbia University | 2 |
| Fred Hutchinson Cancer Center | 2 |
| Wake Forest University Health Sciences | 2 |
| BriovaRx Infusion Services | 1 |
| Fairview University Medical Center | 1 |
| Jasper Therapeutics, Inc. | 1 |
| Myrexis Inc. | 1 |
| National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 1 |
| Pharming Technologies B.V. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Immunologic Deficiency Syndromes | 19 |
| Lymphoma | 5 |
| Leukemia | 4 |
| Granulomatous Disease, Chronic | 3 |
| Multiple Myeloma | 3 |
| Myelodysplastic Syndromes | 3 |
| Anemia, Aplastic | 2 |
| Bone Marrow Failure Disorders | 2 |
| Common Variable Immunodeficiency | 2 |
| Genetic Diseases, Inborn | 2 |
Trials
Showing 1 to 19 of 19. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.